dupilumab与阿司匹林脱敏治疗AERD相关CRSwNP的成本效果分析
本研究比较阿司匹林脱敏与dupilumab治疗阿司匹林加重呼吸道疾病(AERD)相关慢性鼻窦炎伴鼻息肉(CRSwNP)的成本效果。结果显示ESS后阿司匹林脱敏具成本效果,补救性dupilumab亦具成本效果(ICER $135,517.33),而 upfront dupilumab 在任何情景下均不具成本效果(ICER $273,181.32)。
要点
- ESS后阿司匹林脱敏具成本效果,优于适当药物管理。
- 补救性dupilumab具成本效果,ICER为$135,517.33。
- upfront dupilumab在任何情景下均不具成本效果。
核心结论
- 在愿意支付阈值$150,000下,dupilumab作为补救治疗对重度CRSwNP具成本效果。
- dupilumab的成本效果对药物价格和预期生活质量增益最敏感。
研究设计与样本
- 成本效果分析,以质量调整生命年(QALYs)衡量。
- 成本效用分析,以所需修正性内镜鼻窦手术(ESS)次数衡量。
主要发现
- 10年每患者:ESS后适当药物管理花费$54,125.31,修正ESS 2.25次。
- ESS后阿司匹林脱敏花费$53,775.15,修正ESS 2.02次。
- 阿司匹林脱敏联合补救dupilumab花费$121,176.25,修正ESS 1.68次。
- upfront dupilumab花费$185,950.34,修正ESS 1.51次。
关键数值与推荐
- ESS后阿司匹林脱敏具成本效果并优于适当药物管理。
- 补救性dupilumab具成本效果,ICER $135,517.33。
- upfront dupilumab在任何情景下均不具成本效果,ICER $273,181.32。
临床怎么用
- AERD相关CRSwNP患者ESS后优先考虑阿司匹林脱敏治疗。
- dupilumab可作为补救治疗,而非 upfront 使用。
- 需关注药物价格和患者选择以改善dupilumab成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) in the setting of aspirin-exacerbated respiratory disease (AERD) is a disease that is difficult to treat and prone to recurrence. Dupilumab is a promising treatment for these patients, but its cost-effectiveness has not yet been compared with aspirin (acetylsalicyclic acid, or ASA) desensitization, a known and effective treatment. We aimed to compare the cost-effectiveness of ASA desensitization with dupilumab therapy for the treatment of CRSwNP in AERD. METHODS: Analyses of cost-effectiveness, as measured in quality-adjusted life years (QALYs), and cost-utility, as measured in number of required revision endoscopic sinus surgeries (ESSs), were conducted. RESULTS: ASA desensitization after ESS was cost-effective and dominated appropriate medical management. Adding salvage dupilumab was also cost-effective (incremental cost-effectiveness ratio [ICER] $135,517.33), and upfront dupilumab therapy was not cost-effective in any scenario (ICER $273,181.32). The cost-utility analysis demonstrated that, over a 10-year period per patient, appropriate medical management after ESS cost $54,125.31 and resulted in 2.25 revision ESSs, ASA desensitization after ESS cost $53,775.15 and resulted in 2.02 revision ESSs, ASA desensitization with salvage dupilumab cost $121,176.25 and resulted in 1.68 revision ESSs, and upfront dupilumab cost $185,950.34 and resulted in 1.51 revision ESSs. CONCLUSION: Dupilumab for the treatment of severe CRSwNP was found to be cost-effective as salvage therapy under the willingness-to-pay threshold of $150,000. Further analysis highlighted that the cost-effectiveness of dupilumab was most sensitive to drug price and expected gains in quality of life. This suggests that additional investigation into improving patient population selection and tailoring treatment algorithms may improve the cost-effectiveness of dupilumab in specific scenarios.
引用
- Yong M, Wu YQ, Howlett J, et al. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021. PMID: 34309219. doi:10.1002/alr.22865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。